SCHEMBL1491407

SCHEMBL1491407

CC(O)C(NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSL P07711 4/20 0.70
CTSS P25774 4/20 0.70
MME P08473 3/20 0.61
ECE1 P42892 2/20 0.61
CTSK P43235 4/20 0.58
CTSB P07858 3/20 0.58
ATM Q13315 1/20 0.57
MEN1 O00255 1/20 0.54
LMNA P02545 1/20 0.54
KMT2A Q03164 1/20 0.54
CTRB1 P17538 2/20 0.54
ELANE P08246 1/20 0.53
TRPM8 Q7Z2W7 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
RAB9A P51151 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6389671 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL1491409 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL320302 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL6389667 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL1285941 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL10663359 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL1491412 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL14561285 1.00 CTSL (0.70) CTSLCTSSMMEECE1CTSK
SCHEMBL4754315 0.91 CTSL (0.63) CTSLCTSSMMEECE1CTSK
SCHEMBL4754230 0.91 CTSL (0.63) CTSLCTSSMMEECE1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1039886-A4 HIV/FIV PROTEASE INHIBITORS HAVING A SMALL P3 RESIDUE SCRIPPS RESEARCH INST (US) 2001-05-16 EP claimed
EP-1039886-A1 HIV/FIV PROTEASE INHIBITORS HAVING A SMALL P3 RESIDUE The Cripps Research Institute (US) 2000-10-04 EP claimed
WO-1999029311-A1 HIV/FIV PROTEASE INHIBITORS HAVING A SMALL P3 RESIDUE THE SCRIPPS RESEARCH INSTITUTE (US) 1999-06-17 WO claimed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN disclosed
EP-3658569-B1 PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS NAUREX INC (US) 2024-01-31 EP disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 WO disclosed
WO-2023044171-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-03-23 WO disclosed
US-20230000813-A1 COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE INTERVET INC. (US) 2023-01-05 US disclosed
CN-115053184-A Composition for forming EUV resist underlayer film 日产化学株式会社 2022-09-13 CN disclosed
CN-109661398-B Spiro-lactam and di-spiro-lactam NMDA receptor modulators and uses thereof 阿普廷伊克斯股份有限公司 2022-07-05 CN disclosed
US-20220112239-A1 PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS INNOVIVA TRC HOLDINGS LLC 2022-04-14 US disclosed
EP-1081137-A1 Selective inhibitors of aggrecanase in osteoarthritis treatment Pfizer Products Inc. (US) 2001-03-07 EP disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
US-4720484-A Peptide compounds having a nitrogenous polycyclic structure ADIR S.A.R.L. (FR) 1988-01-19 US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP disclosed
EP-0190058-A1 Peptide derivatives with a polycyclic nitrogen structure, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1986-08-06 EP disclosed
US-4452890-A Method of producing L-threonine by fermentation AJINOMOTO COMPANY INCORPORATED (JP) 1984-06-05 US disclosed
EP-0066129-A2 Method for producing L-threonine by fermentation AJINOMOTO CO., INC. (JP) 1982-12-08 EP disclosed
US-3932489-A Process for t-butylating hydroxy- or thiol-substituted amino acids ELI LILLY AND COMPANY (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112239-A1 PROCESS AND INTERMEDIATES FOR SYNTHESIS OF PEPTIDE COMPOUNDS PEPD, VIP, IAPP CTSL 46/4885CTSS 1177/4885MME 517/4885
US-20230000813-A1 COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE PIGS, BTD, BRD1 CTSL 2717/4885CTSS 1568/4885MME 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.